The rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Those shots could provide a longer-lasting and more convenient option than daily insulin and other common treatments for managing diabetes.every day. Meanwhile, roughly a third of people with Type 2 diabetes need insulin injections to keep their blood sugar within a healthy range, according to some. But some resist or delay treatment due to inconvenience and pain, among other reasons, which could worsen their long-term health.dominance in the insulin market.
The patients in the trial were using insulin for the first time and some of them were also taking a GLP-1 drug. The trial studied efsitora in a group of diabetes patients who previously received multiple daily insulin injections. After 26 weeks, both Eli Lilly's new weeklyEli Lilly said efsitora was"safe and well-tolerated" by patients in both studies. The company will present full data from the QWINT-2 trial at the annual meeting of the European Association for the Study of Diabetes. Eli Lilly also expects initial results from three other late-stage studies later this year.
Uber Caregiver marks an expansion of Uber's existing health-care offerings. Bhat's team helps health-care providers and insurance companies arrange for patient rides, as well as the delivery of prescriptions, groceries and other over-the-counter items through the Uber Health dashboard.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk, Eli Lilly drop on Amgen competition concernsNovo Nordisk, Eli Lilly drop on Amgen competition concerns
Read more »
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slideAmgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.
Read more »
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supplyEli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch’s heart monitoring tech was approved for use in clinical…
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supplyEli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch’s heart monitoring tech was approved for use in clinical…
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulinsThe rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Read more »